Olaparib for BRCAness Phenotype in Pancreatic Cancer: Phase II Study
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Olaparib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 06 Feb 2018 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.
- 20 Jan 2018 Results of pool data from two parallel phases II trials (NCT02677038 and NCT02511223) assessing the efficacy of olaparib in advanced PDAC with BRCAness, were presented at the 2018 Gastrointestinal Cancers Symposium.
- 28 Sep 2017 Status changed from active, no longer recruiting to recruiting.